行情

PVCT

PVCT

Provectus Biopha
OTCMQB
0.052
+0.004
+7.92%
交易中 09:30 10/05 EDT
开盘
--
昨收
0.052
最高
--
最低
--
成交量
--
成交额
--
52周最高
0.078
52周最低
0.042
市值
2,173.00万
市盈率(TTM)
-4.8868
分时
5日
1月
3月
1年
5年
暂无数据
PVCT 简况
Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing immunotherapy medicines for different diseases. Its immunotherapy medicines are based on a family of small molecules called halogenated xanthenes (HXs). Its lead HX molecule is named rose bengal disodium (RBD). Its product pipeline includes PV-10 and PH-10. PV-10 is an investigational cancer immunotherapy administered by intralesional (IL) injection and an injectable formulation of cGMP RBD, is undergoing clinical study for adult solid tumor cancers, such as melanoma and gastrointestinal (GI) tumors. PH-10 is an investigational immuno-dermatology agent administered as a topical gel and formulation of cGMP RBD, is undergoing monotherapy clinical study and preclinical study of combination therapy with approved drugs for inflammatory dermatoses. It is also developing clinical programs for the treatment of SARS-CoV-2, Gram-positive bacteria, Infectious Keratosis and others.

微牛提供Provectus Biopharmaceuticals Inc(OTCMQB-PVCT)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的PVCT股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易PVCT股票基本功能。